Results: Baseline %carbOC of the entire study population was positively correlated with BMD of the lumbar spine and femoral neck. Correspondingly, women with low BMD had lower %carbOC at baseline than women with normal BMD but this difference disappeared after 1 y of supplementation with vitamin K 1 ((mean + s.d.) 68 + 11% (95% CI, 64.5 ± 71.2%) vs 72 + 6% (95% CI, 70.1 ± 72.9%), respectively). One year of supplementation with vitamin D 3 showed maximum increases in 25(OH)D of 33 + 29% (95% CI, 24.8 ± 41.8%) and 68 + 58% (95% CI, 50.1 ± 84.6%) in women with normal and low BMD, respectively. During winter, however, a 29% decline in maximum 25(OH)D levels was not prevented in women with low BMD. Conclusion: Daily supplementation of Dutch postmenopausal women with b400 IU vitamin D 3 is indicated to prevent a winter decline in 25(OH)D and to control serum parathyroid hormone levels. Daily supplementation with 80 mg vitamin K 1 seems to be necessary to reach premenopausal %carbOC levels. A stimulatory effect of calcium andaor vitamin D on %carbOC cannot be excluded. Descriptors: postmenopausal women; vitamin D; vitamin K; 25-hydroxyvitamin D; carboxylated osteocalcin; recommendation
Introduction
Vitamins D and K play essential roles in bone metabolism. Calcitriol, the most active vitamin D metabolite, augments active intestinal calcium uptake and reduces serum levels of parathyroid hormone (PTH). Elevated PTH levels are unfavorable since they stimulate bone resorption, bone remodeling and ®nally bone loss (Holick, 1998) . At latitudes 40 north and south of the equator, sunlight exposure is unable to sustain vitamin D 3 photosynthesis in the skin during the winter months. Consequently, circulating 25-hydroxyvitamin D (25(OH)D), which is a reliable marker of vitamin D-status, is lower in winter than in summer (Romagnoli et al, 1999; Meunier, 1999; Shearer, 1997; Utiger, 1998) . Vitamin K is a co-factor for g-glutamylcarboxylase, which catalyzes the post-translational carboxylation of speci®c glutamate residues into g-carboxyglutamic acid (Gla) in proteins involved in blood coagulation and bone metabolism. Osteocalcin is the most intensively studied Gla-protein of bone metabolism. In its carboxylated form, osteocalcin exhibits strong calcium binding properties and is necessary for proper mineralization of new bone (Shearer, 1997; Boskey et al, 1998) . The percentage carboxylated osteocalcin (%carbOC), as calculated from total osteocalcin, was found to be less than 60% in osteoporotic postmenopausal women as compared to 70 ± 80% in young, healthy adults (Douglas et al, 1995; Jie et al, 1996) . Both the percentages of carboxylated prothrombin and %carbOC are functional parameters of vitamin K status, but the latter seems to be more sensitive (Shearer, 1997; Sokoll & Sadowski, 1996) .
To reach adequate 25(OH)D levels in summer, and especially in winter, the Dutch Food Nutrition Council (Dutch Food Nutrition Council, 1992) recommends daily intakes of 100 ± 200 IU (2.5 ± 5 mg) of vitamin D for women 65 y and older. The recommendation is 0 ± 100 IU for the younger postmenopausal women, since they are considered to spend suf®cient time outdoors. A recent survey shows that women 50 y and older consume daily 3.3 ± 3.6 mg of vitamin D, which means that the recommendation is reached (Dutch National Food Consumption Survey, 1998) . Optimum vitamin D status, however, has recently been subject to renewed discussion (Vieth, 1999; DawsonHughes, 1998; McKenna & Freaney, 1998) and was suggested to be b100 nmol 25(OH)DaL (Meunier, 1999) . For vitamin K, the US RDA (National Research Council, 1989) amounts to 65 mg for 50-y-old women, based on the maintenance of plasma carboxylated prothrombin concentrations in the normal range. The daily intake of vitamin K 1 , which is the major form of nutritional vitamin K and the dominant form in bone, is estimated to be 250 mg for 50 y and older Dutch women (Schurgers et al, 1999; Kohlmeier et al, 1996) .
This study aimed to investigate whether the vitamin D and K status of about 60-y-old postmenopausal Dutch women can be improved. For this we selected two groups with documented normal and low bone mineral density (BMD), respectively, and supplemented them with vitamin D 3 , vitamin K 1 , vitamins K 1 D 3 , or placebo during 1 y. Serum 25(OH)D and %carbOC served as parameters of vitamin D and K status, respectively.
Methods

Subjects
The subjects reported in this paper were apparently healthy Caucasian postmenopausal women. They participated in two different studies on the effect of calcium, vitamin D 3 and vitamin K 1 supplementation in women with normal (n 96) or low (n 45) BMD of the lumbar spine. Women with normal and low BMD had lumbar spine T-scores of bÀ1 and`À1 s.d. respectively, as measured with dualenergy X-ray absorptiometry (QDR 2000 and 1000, Hologic Inc., Waltman, MA, USA). The women were at least 5 y postmenopausal and between 50 and 77 y of age. Their baseline characteristics are given in Table 1 . They did not use medication or vitamin andaor mineral preparations known to interfere with bone metabolism, and they were asked to abstain from arti®cial sun bathing during the study period. Excluded were women with acute and chronic illnesses. All women gave their free and informed consent. The Medical Ethical Committees of the University Hospital of Groningen and the Medical Centre Leeuwarden approved the studies.
Supplements and diet
Women with normal BMD were, in a double blind study, randomly allocated to daily supplements that provided 400 IU vitamin D 3 and 80 mg vitamin K 1 (group A), 80 mg vitamin K 1 only (group B), or 2.5 g of skimmed milk powder (placebo). Women with low BMD were, in an open study, randomly allocated to a daily supplement that provided 350 IU vitamin D 3 and 80 mg K 1 (group C) or to a commercially available 400 IU vitamin D 3 tablet (Devaron, Solvay Pharma B.V., Weesp, The Netherlands, group D). All women, except for the ones who were assigned to placebo, received about 1000 mg of additional calcium, which increased total daily calcium intake to 2200 ± 2300 mg. All supplements also contained other minerals and vitamins, such as magnesium, zinc, B-vitamins and vitamin C (data not shown). Compliance, expressed as percentage sachets or tablets taken, was assessed on the basis of emptied package counts and written checklists.
Material and methods
Blood samples were collected at baseline and after 3, 6 and 12 months. Serum was stored at À20 C within 1 h. All samples were taken at ®xed clock times during the day to avoid circadian rhythms. Blood samples from the women with normal BMD were taken in the periods of September ± December (baseline), December ± March (3 months), March ± June (6 months) and September ± December (12 months). Those from the women with low BMD were Vitamins D 3 and K 1 in postmenopausal women A Schaafsma et al collected during the periods of November ± February (baseline), March ± May (3 months), May ± August (6 months) and November ± February (12 months). Serum total osteocalcin and undercarboxylated osteocalcin were measured in the Groningen University Hospital before and after extraction with hydroxyapatite, respectively, using the IRMA of Medgenix-H-Ost (Fleurus, Belgium). The %carbOC was calculated from the difference of undercarboxylated osteocalcin and total osteocalcin. Serum 25(OH)D of the women with normal BMD was determined with a competitive protein binding assay developed in the Groningen University Hospital. This analysis is preceded by solid phase extraction (Chen et al, 1990) . Serum 25(OH)D of women with low BMD were measured at baseline and at 6 and 12 months by the laboratory of the Leeuwarden Hospital, that uses the kit of Incstar (Sorin, Biomedica, Stillwater, MN, USA; Hollis et al, 1993) .
Statistics and data analysis
Between-group differences in baseline characteristics were studied with ANOVA, followed by a Bonferroni-corrected post-hoc test. Within-group and between-group differences in %carbOC and 25(OH)D were studied with nonparametric, two tailed statistical tests (Wilcoxon signed-rank test and the Mann ± Whitney U-test which was preceded by Kruskal ± Wallis test when necessary) since the Kolmogorov ± Smirnov test indicated non-Gaussian distribution of both parameters. We did not evaluate 25(OH)D differences of patients with normal and low BMD. The results of these groups derived from different 25(OH)D analytical methods, and a recent evaluation of these methods by Lips et al (1999) showed substantial differences in their outcomes. Relations between parameters were investigated with the Spearman Rank test. Differences were considered signi®-cant at P 4 0.05. All analyses were done with SPSS 7.0 (SPSS Inc., Chicago, USA).
Results
Women with normal BMD (group A B placebo, n 96) and low BMD (group C D, n 45) differed clearly in BMD as derived from their T-scores (P 4 0.0001) and Z-scores (P`0.005) measured at the various sites (Table 1) . Women with normal BMD had higher body weight (P 0.01), higher BMI (P 0.02) and higher %carbOC (P 4 0.0001), compared with women with low BMD. Although women with normal BMD had signi®cantly higher 25(OH)D at baseline compared with counterparts with low BMD, this may be caused by the use of different 25(OH)D analytical methods.
At baseline and only for the entire population, %carbOC was positively correlated with BMD of the lumbar spine (r 0.32, P`0.005) and femoral neck (r 0.25, P`0.005). This association indicates that low levels of %carbOC accompany low BMD. Vieth, 1999) . Group A also had higher 25(OH)D after 3, 6 and 12 months, compared with baseline (P`0.005), which can especially be attributed to an effect of the ®rst 3 months (P 4 0.0001). There was a modest 25(OH)D increase from 3 to 12 months (P 0.004). 25(OH)D concentrations of group B placebo decreased during the ®rst 3 months (P 4 0.0001) and subsequently increased from 6 to 12 months (P 4 0.0001). The 25(OH)D concentration of group B placebo was after 12 months slightly above baseline (P 0.009). The lower concentration after 3 months in group B placebo coincided with sampling in December ± June, whereas the higher concentration after 12 months coincided with sampling in June ± December. Women with low BMD (groups C D) showed an initial increase of 25(OH)D from 0 to 6 months (P 4 0.0001) and a subsequent decrease from 6 to 12 months (P 4 0.0001) (Figure 1 ; right upper panel). According to the 125 I-labeled radioimmunoassay, 25(OH)D concentrations were 83 + 29 and 59 + 20 nmolal after 6 and 12 months, respectively. At 12 months, 25(OH)D was 46.7 + 48.0% above baseline (P 0.009). The 25(OH)D increase at 6 months and decrease at 12 months (compared with 6 months), coincided with blood samples taken in May ± August and November ± February, respectively.
Effects of vitamin K 1 supplementation
Women with normal BMD who received vitamin K 1 (group A B) had higher %carbOC after 6 months (P 0.009) and 12 months (P 0.001) compared with their counterparts who received placebo (Figure 1 ; lower left panel). Group A B had higher %carbOC after 3, 6 and 12 months, compared with baseline (P 4 0.0001). Increases of %carbOC from 0 to 3 months and 3 to 6 months, and the decrease from 6 to 12 months were signi®cant (P 4 0.0001). After 12 months the level of %carbOC was 72.6 + 6%. The %carbOC level increased in the placebo group during the ®rst 6 months (P 0.001), which was especially an effect of the ®rst 3 months (P 0.031). The %carbOC subsequently decreased from 6 to 12 months (P 0.005) to reach levels comparable with baseline at 12 month, 65.1 + 8.9%. The higher levels at 6 months coincided with samples taken in December ± June, whereas the lower levels at 12 months were found in samples collected in June ± December.
Women with low BMD who received vitamin K 1 (group C) did not differ from women who did not receive vitamin K 1 (group D) after 3, 6 and 12 months (Figure 1 ; lower right panel). The %carbOC of group C was higher at 3, 6 and 12 months, compared with baseline (P 0.025, 4 0.0001 and 4 0.0001, respectively). Also the increases from 3 to 6 and 3 to 12 months were signi®cant (P 0.05). In group D, the %carbOC after 6 and 12 months were higher than baseline (P 4 0.0001 and 0.006, respectively). In this group, the increases from 3 to 12 and 6 to 12 months were signi®cant (P 0.03 and 4 0.0001, respectively). After 12 months, %carbOC levels were 69.0 + 11.4% and 66.7 + 11.5% for groups C and D respectively. Both groups showed increases of the percentage women who had optimal %carbOC after 12 months at the expense of suboptimal and low %carbOC (Figure 2) . Levels of %carbOC in vitamin K 1 supplemented women with normal BMD (group A B; Figure 1 bottom left panel) were higher at baseline and after 3 and 6 months (P 4 0.0001) compared with vitamin K 1 supplemented counterparts with low BMD (group C, Figure 1 ; bottom right panel).
Discussion
This study shows that Dutch postmenopausal women with low lumbar spine BMD (T-score 4 À1) have lower %carbOC, than postmenopausal women with normal BMD (T-score b À1) ( Table 1 ). This lower %carbOC was corrected after supplementation with 80 mg vitamin K 1 (Figure 1 ). The %carbOC increase in women with low Table 1 , for supplements of the groups see legend of Figure 1 . %carbOC is a parameters of vitamin K status. Classi®cation of %carbOC is according to Jie et al (1996) . %carbOC normal BMD (K1) is group A B (n 69); %carbOC normal BMD (placebo) is the placebo group (n 27); %carbOC low BMD (K1) is group C (n 22); %carbOC low BMD (D3) is group D (n 23).
Vitamins D 3 and K 1 in postmenopausal women A Schaafsma et al BMD and possibly also with normal BMD may, however, not be merely attributable to vitamin K 1 but also to vitamin D 3 andaor calcium. Vitamin D 3 supplementation (350 ± 400 IU) improved vitamin D-status in both groups of women with normal and low BMD, but was unable to prevent a decline of 25(OH)D during the winter months in women with low BMD. With the objective of minimizing bone loss and stimulating proper mineralization of new bone, we conclude that a large proportion of apparently healthy Dutch postmenopausal women, in particular those with low BMD, might need additional daily intakes of at least 400 IU vitamin D 3 and 80 mg of vitamin K 1 , in combination with suf®cient calcium.
Low 25(OH)D concentrations may imply suboptimal mineralization of newly formed bone and increased bone resorption secondary to increased PTH secretion. Suboptimal 25(OH)D concentrations may not be able to give rise to maximum PTH suppression (Vieth, 1999; McKenna & Freaney, 1998) . Supplementation with 350 ± 400 IU vitamin D 3 markedly improved 25(OH)D concentrations of women with normal and low BMD (Figure 1 ). In women with low BMD, however, this dose was not suf®cient to hold the higher 25(OH)D concentrations as achieved during summer months. In November ± February, 25(OH)D levels decreased by 29%. A comparable winter decrease was found in women with normal BMD who received placebo. Since no differences are expected in vitamin D metabolism between the women with low and normal BMD, a lower vitamin D-status at baseline can only explain the lower response to vitamin D supplementation by women with low BMD. Prevention of a 25(OH)D dip in winter is important, since BMD of the femoral neck shows the same seasonal variation as 25(OH)D (Dawson-Hughes et al, 1995) . Others have shown that a 25(OH)D decline during winter can be prevented with 700 ± 800 IU vitamin D 3 per day (DawsonHughes et al, 1995 (DawsonHughes et al, , 1997 . These higher intakes were found to be associated with lower fracture risk Dawson-Hughes et al, 1997) . Taken together, our study shows that a daily vitamin D 3 supplementation with 400 IU is suf®cient for healthy postmenopausal women with normal BMD, which is in line with the recent US recommended adequate intake (Standing Committee on the Scienti®c Evaluation of Dietary Reference Intakes, 1997). Postmenopausal women with low BMD, however, need higher intakes possibly to correct for a lower habitual vitamin D consumption.
Therefore, an additional intake of 700 ± 800 IU vitamin D may be considered for all postmenopausal women, notably because of the favorable results obtained by Dawson-Hughes et al (1995 , 1997 . Such an intake is considered to be safe (Vieth, 1999; Sparks, 1994) and far below the vitamin D tolerable upper intake level of 2000 IU (Standing Committee on the Scienti®c Evaluation of Dietary Reference Intakes, 1997).
Baseline %carbOC of the whole group was positively correlated with BMD of the lumbar spine and femoral neck. This ®nding agrees with the inverse correlation between undercarboxylated osteocalcin and BMD as reported by others. They suggested to use high undercarboxylated osteocalcin (ie low %carbOC) as an indicator of hip fracture risk (Szulc et al, 1994 (Szulc et al, , 1996 . The %carbOC is involved in proper mineralization of new bone (Shearer, 1997; Boskey et al, 1998) , and reduced bone loss in ovarietomized mice (Wolf, 1996) . Levels found in premenopausal women (70 ± 80%) may in this respect be regarded as optimal (Douglas et al, 1995; Jie et al, 1996) . Using this criterion we found that in our study 93% of the women with low BMD and 55% of the women with normal BMD had suboptimal levels at baseline (Figure 2) . The mean %carbOC of the women with low BMD is comparable with levels reported for patients with osteoporosis (59%) (Jie et al, 1996) . Women (n 6) treated with coumarins, which block the vitamin K-cycle, had a mean %carbOC level of 40.2% (95% CI, 34 ± 48%) as established with our method (personal, communication) . On the basis of a previous study conducted in The Netherlands, it can be assumed that baseline vitamin K 1 intake by our women amounts to about 250 mg per day (Schurgers et al, 1999) . This intake is considerably higher than the current US recommendation (National Research Council, 1989) (65 mgaday) which is based on the less sensitive hepatic vitamin-K dependent proteins (Booth et al, 1999) . Daily supplementation with 80 mg vitamin K 1 was nevertheless found to cause sizable increases of the %carbOC towards levels encountered in premenopausal women (Figure 2 ). Somewhat to our surprise we found that %carbOC in women with low BMD did not only increase upon vitamin K 1 supplementation, but also after daily supplementation with 400 IU vitamin D 3 and 1000 mg of calcium as shown by group D (Figure 1) . A role of vitamin D in osteocalcin carboxylation has previously been suggested by others, although the mechanism is as yet unknown (Shearer, 1997; Meunier, 1999) . Women with normal BMD showed an increased %carbOC compared with placebo. Since the placebo lacks both vitamin K 1 and calcium, a stimulatory effect of calcium on %carbOC cannot be excluded. However, as yet this is not supported by any study we know of. An effect of vitamin D is not expected because no difference was found between groups A (with vitamin D) and B (no vitamin D). Based on these observations, it seems that an estimated daily total intake of about 330 mg vitamin K 1 , andaor higher intakes of calcium andaor vitamin D, are necessary to reach and maintain premenopausal %carbOC in all healthy postmenopausal women. This intake of vitamin K 1 is far below the safe maximal daily intake (32.5 mg; Olson, 1994) and considerably lower than the 1 mg dosage used in the treatment of postmenopausal colles fractures (Douglas et al, 1995) . For patients on anti-coagulant therapy, however, the suggested amount of vitamin K may weaken the therapy. These patients bene®t from constant dietary intakes of vitamin K on the level of the US RDA (Booth & Centurelli, 1999) .
In summary, our study shows that healthy postmenopausal women with low BMD also have low serum %carbOC when compared with counterparts with normal BMD. Supplementation with 350 ± 400 IU vitamin D 3 for 12 months increased 25(OH)D in all women, however, it did not prevent a decrease in the maximum achieved 25(OH)D concentrations during winter in those with low BMD. Supplementation with 80 mg vitamin K 1 is suggested to increase %carbOC to premenopausal values in all women, but an additional effect of vitamin D andaor calcium on %carbOC cannot be excluded. An increased %carbOC is a good proxi variable for BMD in postmenopausal women. Taken together, we recommend daily additional intakes of 700 ± 800 IU vitamin D and 80 mg vitamin K 1 by postmenopausal women to support bone health. These supplements give rise to total dietary intakes that are considerably higher than current US recommendations, but much lower than the assumed safe maximum daily intakes for both of these vitamins (Olson, 
